Caption Management’s Beam Therapeutics BEAM Stock Holding History

Caption Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-178,352	Closed	-$4.95M	–	1569
2025 Q4	$4.94M	Buy	+178,352	New	+$4.55M	0.03%	523
2025 Q3	–	Sell	-348,435	Closed	-$6.93M	–	1668
2025 Q2	$5.93M	Buy	+348,435	New	+$6.07M	0.07%	355
2023 Q1	–	Sell	-4,700	Closed	-$185K	–	1097
2022 Q4	$184K	Buy	+4,700	New	+$211K	﹤0.01%	1077
2021 Q2	–	Sell	-2,533	Closed	-$203K	–	1300
2021 Q1	$203K	Buy	+2,533	New	+$241K	﹤0.01%	918

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Caption Management's BEAM Position: Q1 2026 in Review

Caption Management sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 178,352 shares — an estimated $4.95M sold.

Caption Management first reported a position in BEAM in Q1 2021 and held it in 4 quarters. The position peaked at $5.93M in Q2 2025. 253 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

Caption Management reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
Caption Management sold 178,352 Beam Therapeutics shares in Q1 2026, an estimated $4.95M.
Caption Management first reported a position in Beam Therapeutics in Q1 2021 and held it in 4 quarters.
Caption Management's Beam Therapeutics position peaked at $5.93M in Q2 2025.
253 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.